Therapy Areas: Infectious Diseases
Veracyte partners with MAVIDx to develop high volume COVID-19 testing
29 July 2020 -

Genomic diagnostics company Veracyte Inc (Nasdaq:VCYT) said on Wednesday that it has entered into an agreement with MAVIDx for the start-up to develop ultra-high throughput genomic testing for SARS-CoV-2, the virus that causes COVID-19, on Veracyte's nCounter diagnostics platform.

The two companies aim to enable diagnostic testing and population screening for COVID-19 at an unprecedented scale -- up to 40,000 samples per day -- through technology that attaches molecular barcodes to individual RNA molecules of the virus.

Krassen Dimitrov, CEO of MAVIDx, said that the COVID-19 pandemic has created a need for scalable diagnostic testing and population screening that cannot be addressed with current technology.

"With our proprietary technology that allows patient results to be assessed from a highly multiplexed assay configuration, combined with the nCounter system's proven accuracy and ability to perform high-throughput testing in an easy-to-use manner, we believe we can help address this growing global health need," Dimitrov added.

Under the agreement, MAVIDx will develop, validate, secure regulatory approvals for and commercialise its SARS-CoV-2 and other infectious disease tests on the nCounter system. Veracyte has secured an equity stake in MAVIDx and will supply the company's infectious disease test kits and nCounter instruments to support laboratories and other entities in the United States and in global markets.

No financial details were disclosed.